| Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. | |
| | |
MedLine Citation:
|
PMID: 17227788 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To assess the efficacy and safety of adjunctive antiarrhythmic drug therapy for preventing implantable cardioverter defibrillator (ICD) therapies. METHODS AND RESULTS: We conducted a systematic literature search to identify all randomized, controlled trials assessing the efficacy of adjunctive antiarrhythmic drug therapy. Trial data were reviewed and extracted independently by two investigators in an unblinded, standardized manner. Eight trials including a total of 1889 patients were analysed. There was heterogeneity in the type of antiarrhythmic used in the treatment arm (amiodarone, sotalol, azimilide, and dofetilide) as well as in the control group (five trials compared with placebo and three trials compared with beta-blocker). The main outcome, risk of shock therapy, was reduced when comparing amiodarone plus beta-blocker with beta-blocker alone (HR 0.27; 95% CI 0.14-0.52) and when comparing sotalol with placebo (HR 0.55; 95% CI 0.4-0.78). The effect was not conclusive when comparing sotalol with other beta-blocker (HR 0.61; 95% CI 0.37-1) and azimilide or dofetilide with placebo (HR 0.78; 95% CI 0.58-1.04 and HR 0.67; 95% CI 0.43-1.04, respectively). Although there were some benefits for secondary outcomes in all antiarrhythmics, the magnitude of the benefit was higher with amiodarone. CONCLUSION: Amiodarone is the most effective treatment to reduce ICD shock therapies. The benefit of other antiarrhythmics is limited to secondary outcomes. |
| | |
Authors:
|
Ignacio Ferreira-González; Laura Dos-Subirá; Gordon H Guyatt |
Related Documents
:
|
16281998 - Randomised controlled trial of a lay-led self-management programme for bangladeshi pati... 19635338 - Transcutaneous electrical nerve stimulation and transcutaneous spinal electroanalgesia:... 20133488 - Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin recep... 20211908 - Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. 21368238 - Point-of-care testing for hb a1c in the management of diabetes: a systematic review and... 21925738 - Genuine clinical predictors of bipolar ii disorder: an exploration of temporal and cont... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2007-01-16 |
Journal Detail:
|
Title: European heart journal Volume: 28 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-02-16 Completed Date: 2007-11-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: England |
Other Details:
|
Languages: eng Pagination: 469-77 Citation Subset: IM |
Affiliation:
|
Epidemiology Unit, Department of Cardiology, Paseo Vall d'Hebron Hospital, Barcelona 119-129, 08035, Spain, and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. nacho_ferreira@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Arrhythmia Agents
/
therapeutic use* Arrhythmias, Cardiac / therapy* Chemotherapy, Adjuvant Clinical Trials as Topic Defibrillators, Implantable* Humans Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevat...
Next Document: The common non-synonymous variant G38S of the KCNE1-(minK)-gene is not associated to QT interval in ...